Innocan Pharma Corporation

Recent News

• Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product

  Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its vaginal derma product (the "Product").The results of the Trial demonstrate that Innocan's Product, which contains cannabinoids, phytoestrogens, hyaluronic acid, and probiotics, effectively reduced the symptoms, and improved overall vaginal health.The 56-day Trial...

  2023-03-23 4:00 AM EDT
• Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team

  Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is excited to announce the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field.Innocan CEO, Iris Bincovich, stated, "We are excited to announce the appointment of a dedicated...

  2023-03-17 3:30 AM EDT
• Innocan Pharma Announces First Patent Grant in the United States

  This is the first fully granted patent of Innocan in the United StatesThe Patent covers Innocan's proprietary cannabis-based pain relief topical This serves as an indication of Innocan's growing intellectual property portfolioHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 12, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property (IP) portfolio, is pleased to announce...

  2023-03-12 11:18 AM EDT
• Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial

  "Lady", an 11-year-old female dog was presented to Innocan labs suffering from severe autoimmune mediated polyarthritis.Lady was treated with Glycoflex, steroids, and hydrotherapy, but still suffered pain and had difficulty walking more than a few steps.Lady was administered Innocan's liposomal CBD injection and experienced significant improvement, which lasted more than five weeks, indicating the long-acting nature of the liposomal CBD formulation.Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 21, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF)...

  2023-02-21 5:22 AM EST
• Innocan Pharma Provides Annual "State of the Business" Update

  Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 16, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report an annual "State of the Business" update, including with respect to the company's advancements in Research, Intellectual Property and Commercialization, alongside announcing the closing of a non-brokered private placement offering of 1,982,000 units...

  2023-02-16 4:00 PM EST
• Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field

  Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's commercialization of IP in the veterinary field. The principal of Benitz Consulting is Dr. Antonio Benitz, ex Novartis Animal Health and Pharmacia Animal...

  2022-12-02 4:00 PM EST
• Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021

  Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth and are confident in our long-term outlook" says Iris...

  2022-11-29 3:00 AM EST
• Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee

  Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Givi Topchishvili will join the advisory team to support Innocan's goals to expand...

  2022-11-18 2:30 AM EST
• Innocan Pharma Goes Live with Priority(TM) ERP System

  Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 9, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the successful implementation of Priority Software's Priority™ Enterprise Resource Planning (ERP). The new Priority™ ERP system includes financial, logistics, and revenue analysis modules. The new system will optimize numerous financial and procurement processes...

  2022-11-09 4:00 PM EST
• Innocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022

  Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce its participation in a webinar titled "Investor Day: Companies Disrupting The World We Live In", co-hosted by IR Labs Inc. ("irlabs") and the NEO Exchange. The webinar will take place on Wednesday, November 2,...

  2022-10-25 3:00 AM EDT